文献速递免疫规划卫生政策与健康促进

量化英格兰延迟第二剂新冠疫苗接种的效果:一项数学建模研究

Quantifying the effect of delaying the second COVID-19 vaccine dose in England: a mathematical modelling study.
PubMed 文献 · Lancet Public Health · 2023-02-09

该研究使用基于英格兰COVID-19监测数据的SARS-CoV-2传播模型,比较将第二剂疫苗间隔从3周延长至12周与真实接种策略的疫情轨迹。结果显示,在2020年12月8日至2021年9月13日期间,12周策略较3周策略避免了约58 000例COVID-19住院和10 100例死亡,且在所有敏感性分析中3周策略均导致更多住院。按年龄组分析,12周策略在2021年春季导致老年人住院和死亡更多,但在2021年夏季delta变异株出现后则更少。

要点

  • 在2020年12月8日至2021年9月13日期间,12周策略较3周策略避免了约58 000例COVID-19住院和10 100例死亡。
  • 所有敏感性分析中,3周策略均导致更多住院。
  • 12周策略在2021年春季导致老年人住院和死亡更多,但在2021年夏季delta变异株出现后更少。

核心结论

  • 英格兰延迟第二剂疫苗接种策略基于有限疫苗供应和疫情增长背景下早期真实世界疫苗有效性数据,快速为更大比例人群提供部分(单剂)疫苗诱导保护成功减少了COVID-19住院和死亡总体负担。

研究设计与样本

  • 使用先前描述的SARS-CoV-2传播模型,以贝叶斯证据合成框架校准至英格兰COVID-19监测数据(包括住院、医院占用、血清阳性率和人群PCR检测数据),比较3周间隔的反事实情景与12周的真实接种策略,并估计和比较每日感染、住院和死亡数;敏感性分析涵盖一系列疫苗有效性和减弱假设。

主要发现

  • 在2020年12月8日至2021年9月13日期间,12周策略下接种第一剂疫苗的人数高于3周策略。
  • 延迟第二剂间隔从3周至12周避免了中位数58 000例COVID-19住院(3周策略累计住院291 000例[95%可信区间275 000-319 000] vs 12周策略233 000例[229 000-238 000])和10 100例死亡(3周策略死亡64 800例[60 200-68 900] vs 12周策略54 700例[52 800-55 600])。
  • 3周策略较12周策略导致更多感染。
  • 所有敏感性分析中,3周策略均导致更多住院。
  • 按年龄组分析,12周策略在2021年春季导致老年人住院和死亡更多,但在2021年夏季delta变异株出现后更少。

关键数值与推荐

  • 3周策略累计住院291 000例(95%可信区间275 000-319 000)vs 12周策略233 000例(229 000-238 000),12周策略较3周策略减少58 000例住院(中位数)。
  • 3周策略死亡64 800例(95%可信区间60 200-68 900)vs 12周策略54 700例(52 800-55 600),12周策略较3周策略减少10 100例死亡(中位数)。
  • 3周策略较12周策略导致更多感染。
  • 所有敏感性分析中,3周策略均导致更多住院。
  • 按年龄组分析,12周策略在2021年春季导致老年人住院和死亡更多,但在2021年夏季delta变异株出现后更少。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The UK was the first country to start national COVID-19 vaccination programmes, initially administering doses 3 weeks apart. However, early evidence of high vaccine effectiveness after the first dose and the emergence of the SARS-CoV-2 alpha variant prompted the UK to extend the interval between doses to 12 weeks. In this study, we aimed to quantify the effect of delaying the second vaccine dose in England. METHODS: We used a previously described model of SARS-CoV-2 transmission, calibrated to COVID-19 surveillance data from England, including hospital admissions, hospital occupancy, seroprevalence data, and population-level PCR testing data, using a Bayesian evidence-synthesis framework. We modelled and compared the epidemic trajectory in the counterfactual scenario in which vaccine doses were administered 3 weeks apart against the real reported vaccine roll-out schedule of 12 weeks. We estimated and compared the resulting numbers of daily infections, hospital admissions, and deaths. In sensitivity analyses, we investigated scenarios spanning a range of vaccine effectiveness and waning assumptions. FINDINGS: In the period from Dec 8, 2020, to Sept 13, 2021, the number of individuals who received a first vaccine dose was higher under the 12-week strategy than the 3-week strategy. For this period, we estimated that delaying the interval between the first and second COVID-19 vaccine doses from 3 to 12 weeks averted a median (calculated as the median of the posterior sample) of 58 000 COVID-19 hospital admissions (291 000 cumulative hospitalisations [95% credible interval 275 000-319 000] under the 3-week strategy vs 233 000 [229 000-238 000] under the 12-week strategy) and 10 100 deaths (64 800 deaths [60 200-68 900] vs 54 700 [52 800-55 600]). Similarly, we estimated that the 3-week strategy would have resulted in more infections compared with the 12-week strategy. Across all sensitivity analyses the 3-week strategy resulted in a greater number of hospital admissions. In results by age group, the 12-week strategy led to more hospitalisations and deaths in older people in spring 2021, but fewer following the emergence of the delta variant during summer 2021. INTERPRETATION: England's delayed-second-dose vaccination strategy was informed by early real-world data on vaccine effectiveness in the context of limited vaccine supplies in a growing epidemic. Our study shows that rapidly providing partial (single-dose) vaccine-induced protection to a larger proportion of the population was successful in reducing the burden of COVID-19 hospitalisations and deaths overall. FUNDING: UK National Institute for Health Research; UK Medical Research Council; Community Jameel; Wellcome Trust; UK Foreign, Commonwealth and Development Office; Australian National Health and Medical Research Council; and EU.

来源:Lancet Public Health,查看原文。版权归原作者所有。

引用

  1. Imai N, Rawson T, Knock ES, et al. Quantifying the effect of delaying the second COVID-19 vaccine dose in England: a mathematical modelling study. Lancet Public Health. 2023. PMID: 36774945. doi:10.1016/S2468-2667(22)00337-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。